Search
Search Results
-
Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma
PurposeThyroid dysfunction is the most common immune-related adverse event during anti-programmed cell death 1 (anti-PD-1) therapy. In this study, we...
-
A CT-based radiomics nomogram for predicting the progression-free survival in small cell lung cancer: a multicenter cohort study
PurposeTo develop a radiomics nomogram based on computed tomography (CT) to estimate progression-free survival (PFS) in patients with small cell lung...
-
A prognostic model for predicting progression-free survival in patients with advanced non-small cell lung cancer after image-guided microwave ablation plus chemotherapy
ObjectivesThis study aimed to build and validate a prediction model that can predict progression-free survival (PFS) in patients with advanced...
-
IDH1 mutation is associated with improved resection rates, progression-free survival and overall survival in patients with anaplastic astrocytomas
PurposeThe introduction of molecular markers in to the diagnosis of gliomas has changed the therapeutic approach to this tumors. The aim of this...
-
Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report
BackgroundConcomitant multiple myeloma (MM) and other primary malignancies is rare. Therefore, the treatment outcomes of patients with these...
-
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study
BackgroundA recent large real-world study conducted in the United States reported the effectiveness of palbociclib plus aromatase inhibitor in...
-
Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
BackgroundFirst-line standard-of-care therapy for advanced cholangiocarcinoma is gemcitabine plus cisplatin; there is no established second-line...
-
Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer
PurposeTo investigate the potential clinical importance of continuing immunotherapy beyond progression in patients with advanced non-small-cell lung...
-
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial
PurposeThe objective was to develop a pharmacokinetic-pharmacodynamic (PK-PD) model linking everolimus and sorafenib exposure with biomarker dynamics...
-
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
IntroductionDaratumumab plus lenalidomide and dexamethasone (D-Rd) and bortezomib plus lenalidomide and dexamethasone (VRd) are commonly used...
-
Does first-line immunotherapy impact the efficacy of later treatments: a discussion on the use of second progression-free survival as a research endpoint
Currently, cancer immunotherapy efficacy is measured by endpoints, such as progression-free survival and overall survival, that are unable to reflect...
-
Disease survival and progression in TARDBP ALS patients from Sardinia, Italy
BackgroundCommon genes implicated in amyotrophic lateral sclerosis (ALS) development may also influence its progression rate. The C9orf72 mutations...
-
A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer
BackgroundThe epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are a first-line therapy for non-small cell lung cancer...
-
Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients
Approximately 31% of patients diagnosed with multiple myeloma (MM) have pre-existing hypertension, but its effects on patient survival have not been...
-
Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis
PurposeTo synthesize the evidence on the impact on progression-free survival (PFS) and overall survival (OS) of supramaximal resection (SMR) over...
-
CT-based radiomics signature analysis for evaluation of response to induction chemotherapy and progression-free survival in locally advanced hypopharyngeal carcinoma
ObjectivesTo establish and validate a CT radiomics model for prediction of induction chemotherapy (IC) response and progression-free survival (PFS)...
-
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial
PurposeTo evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic...
-
Impact of Ovarian Cancer Surgery Volume on Overall and Progression-Free Survival: A Population-Based Retrospective National French Study
BackgroundData are limited on the relationship between ovarian cancer surgery volume and outcomes in France.
MethodsFor this retrospective,...
